The alteration of genetic material held within a person’s cells as a way of treating or preventing disease is the simple, common definition of gene therapy.
TORONTO (PRWEB) October 30, 2019
The impact that oncogenic drivers have on our ability to define a population and ensure equal access to treatment is becoming more critical.
In a free session on Monday, November 18, 2019 at 11am EDT (4pm GMT/UK) join guest speakers from Synteract including Christopher Heckman, Vice President of Oncology Development and Derek Ansel, Director of Rare & Orphan Diseases for a discussion about these challenges, with strategies and real-life solutions to support patients, sites and sponsors.
The alteration of genetic material held within a person’s cells as a way of treating or preventing disease is the simple, common definition of gene therapy. This type of therapy is rapidly progressing within the world of oncology, for both treatment and prevention of cancers. However, the future of gene therapy presents some unique questions and challenges. Are we heading in the right direction? What are the ethical considerations? And how do we ensure access to these therapies?
For more information or to register for this event, visit The Ever-Increasing Impact of Gene Therapy in Rare Oncology Trials.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Tel: +1 (416) 977-6555 ext 400